New FDA framework tilts toward consistency over flexibility
Then-acting FDA leaders said over the summer that regulatory flexibility wasn't the standard they were striving for when the agency gauges rare disease drugs. Now, a more consistent system for assessing
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.